C3 Targeted Complement Therapy for Chronic Periodontitis - A Scoping Review.

Area of Science:

• Periodontology
• Immunology
• Pharmacology

Background:

• Chronic Periodontitis (CP) involves dysbiotic bacteria and immune subversion, leading to destructive inflammation and bone loss.
• Porphyromonas gingivalis plays a key role by subverting complement component C5aR, driving C3-dependent inflammation in CP.
• Animal studies suggest complement C3 inhibition can mitigate inflammatory bone loss in CP.

Purpose of the Study:

• To review the role of complement C3 targeted therapy for Chronic Periodontitis (CP).
• To evaluate the efficacy of C3 inhibitors in managing periodontal inflammation and bone loss.

Main Methods:

• A scoping review of original studies was conducted.
• Literature search performed in Medline (PubMed), Scopus, Web of Science, and Embase.
• Four relevant articles were selected for detailed analysis.

Main Results:

• Included studies comprised 3 animal studies and 1 Phase IIa clinical trial.
• Complement C3 targeted therapy demonstrated a reduction in inflammatory and clinical periodontal parameters in CP.
• AMY-101 was identified as a potential C3 inhibitor for CP treatment.

Conclusions:

• Complement C3 targeted therapy shows potential as an adjunct to non-surgical periodontal treatment for CP.
• Further clinical trials are necessary to validate these promising results.
• Targeting complement C3 represents a novel therapeutic strategy for managing Chronic Periodontitis.